Growth for peptide and longevity programs
Peptide Therapy
BPC-157, TB-500, CJC-1295 and the rest of the longevity menu. Real demand, sold through compounding pharmacies, and the one telehealth category where paid ads are mostly closed no matter what you certify.
How it is sold
The model, before the rules.
A quiz or a consult books a provider visit, the provider writes for a compounded peptide, and a partner pharmacy ships a monthly protocol. The regulatory ground under that model moved twice. In late 2023 and 2024 FDA placed nineteen popular peptides, including BPC-157, CJC-1295, ipamorelin, AOD-9604, MOTS-c and thymosin alpha-1, in Category 2 of its 503A bulk-substances list, meaning the agency saw significant safety risks and compounders were told not to use them. In April 2026 FDA pulled twelve of those out of Category 2 after the nominations behind them were withdrawn, and its compounding advisory committee reviewed BPC-157 in July 2026. Leaving Category 2 is not the same as being placed on the approved list, and none of these peptides is an FDA-approved drug. The market is still open for business; the substances are still unapproved.
How it gets restricted
An unapproved drug is unadvertisable on Meta, Google and TikTok, and no certification changes that. LegitScript certifies the business, its prescribers and its pharmacies; it does not approve a drug. Google's healthcare policy prohibits unapproved pharmaceuticals and speculative treatments outright, and Meta reviews peptide products under its drugs rule as unapproved substances. Accounts in this category are lost, not restricted, because the platforms treat a peptide ad as an attempt to sell an unapproved pharmaceutical rather than as a wording problem.
Paid outlookClosed to paid
Policy by platform
Where a platform asks for LegitScript, it means LegitScript certification: the third-party check Meta and Google require before a telehealth business can name a prescription drug in an ad. It certifies the business, its prescribers and its pharmacies. It does not change what a drug is.
- Meta
- Prescription drugs need LegitScript certification and written authorization, and that path assumes an approved drug. Peptides that are not FDA-approved are reviewed as unapproved substances and rejected; repeat submissions escalate to account loss. Longevity clinic services, provider consults and lab panels can run without naming a compound.
- Google Ads
- The healthcare and medicines policy prohibits unapproved pharmaceuticals and supplements and speculative or experimental treatments. There is no certification for an unapproved substance. Clinic, consult and longevity-program intent is open.
- TikTok
- Prescription medicine is not allowed as an ad subject in the US, and unapproved substances are prohibited everywhere. Provider and brand content only.
Policy pages read 2026-08-30. Meta: Drugs and pharmaceuticals · Meta: Health and wellness · Meta: Personal attributes · Google: Healthcare and medicines · Google: Prescription drug services certification. Full policy tracker
What we run
The plan for peptides.
- Channels
- Paid search and Meta on the longevity consult, the lab panel and the provider. Organic search and email carry the peptide-specific demand, because that is where it can be answered. Provider referral and clinician content compound under both.
- Creative that passes
- The clinic, the physician, the labs, the first visit. No compound names, no mechanism claims, no "healing" or "recovery" language. Peptide education lives on the site and in email, not in an ad.
- Landing page
- A program page for the consult, with the peptide menu one click deeper and written as clinician education with the unapproved status stated. The ad never lands on a product.
- Tracking
- Server-side events with generic names (lead, qualified, booked, purchase) and only hashed identifiers. The ad click ID rides a bridge token into the intake platform, so the consult and the prescription land on the campaign that produced them even though the visitor left our page to book.
What we measure
- CPQL
- Cost per qualified lead on the consult or lab-panel offer, by channel.
- Consult booked
- Provider visit scheduled, attributed to paid, organic or referral.
- Rx issued
- Protocol prescribed after the visit, reported from the intake platform.
- 90-day retention
- Patients still on a protocol at month three, by acquisition source.
Reported weekly by campaign from the tracking installed in the first two weeks. We publish the definitions, not a benchmark, because the number depends on your price, your states and your pharmacy.
Commitments
What is done by which day.
A written channel plan that says which demand paid can reach and which it cannot
Tracking live across paid, organic, email and referral so the sources can be compared
Consult-intent campaigns live on Google and Meta with no compound named
Email and content program shipped for the peptide-specific demand
Days count from kickoff. Certification timelines belong to LegitScript and the platforms, so campaigns that need drug terms start on program intent and add them when approval lands.
Peptides questions
What brands in this category ask first.
Will LegitScript certification let us advertise peptides?
No. LegitScript certifies that the business, its prescribers and its pharmacies are legitimate. It does not make an unapproved drug advertisable, and Google and Meta both treat non-FDA-approved peptides as unapproved substances regardless of who is selling them.
FDA moved BPC-157 out of Category 2. Does that change the ads?
Not yet. In April 2026 FDA removed twelve peptides from Category 2 of its 503A bulk-substances list after the nominations were withdrawn, which lifts the safety-risk designation but does not place them on the approved list or make them approved drugs. Platform policy keys on approval, so the advertising position is unchanged until that happens.
So how does a peptide program grow?
On the consult and the clinic in paid, and on organic search, email, clinician content and provider referral for the peptide-specific demand. Programs that try to force the compound into a Meta ad lose the account; programs that build the other channels keep compounding.
Can we run sermorelin or other formerly approved peptides?
Treat them the same way. Status varies by substance and changes often, and the platforms do not distinguish. The ad names the program and the provider; the product detail lives on the page.
Next step
Start with the audit.
We read your live ads, landing pages and pixel against the rules on this page and send back the flags and the plan. If the account is already restricted, the rescue is the faster door.
Growth audit
See where your growth is leaking.
We audit the funnel, the tracking, and the compliance posture, then hand you the roadmap. The people writing it have run the same funnel from the inside. You keep it whether or not we work together.
- Reviewed
- Funnel, tracking, and compliance posture
- Discussed
- One 30-minute call with the operator on your account
- Delivered
- A written roadmap within 5 business days